CellVax Therapeutics, Inc
CellVax Therapeutics is a clinical-stage private company focused on research, development, and innovation in anti-cancer treatments. They have developed a proprietary personalized tumor cell-based immunotherapy platform, aiming to stimulate the immune system to recognize and destroy tumor cells. Their lead product, FK-PC101, is designed for prostate cancer patients at higher risk of recurrence after prostatectomy, utilizing the patient's cancer cells to create specific Tumor Presenting Cells (TPC) that induce a multi-neoantigen immune response.
Industries
Nr. of Employees
small (1-50)
CellVax Therapeutics, Inc
Miami, Florida, United States, North America
Products
Personalized autologous tumor cell vaccine (lead clinical candidate)
An autologous vaccine candidate manufactured from a patient’s tumor cells modified ex vivo to express MHC class II and loaded with antigen to stimulate both CD4+ helper and CD8+ cytotoxic T cell responses.
Personalized autologous tumor cell vaccine (lead clinical candidate)
An autologous vaccine candidate manufactured from a patient’s tumor cells modified ex vivo to express MHC class II and loaded with antigen to stimulate both CD4+ helper and CD8+ cytotoxic T cell responses.
Services
cGMP production partnerships for personalized cell therapies
Collaborative manufacturing of personalized autologous cell therapy batches with CDMO partners to support clinical trials.
Clinical trial conduct and management
Design and execution of early- and mid-stage clinical studies, including adaptive Phase II trials and outcome analysis for disease‑free survival.
cGMP production partnerships for personalized cell therapies
Collaborative manufacturing of personalized autologous cell therapy batches with CDMO partners to support clinical trials.
Clinical trial conduct and management
Design and execution of early- and mid-stage clinical studies, including adaptive Phase II trials and outcome analysis for disease‑free survival.
Expertise Areas
- Personalized cancer immunotherapy
- Autologous cell therapy development
- Ex vivo cell engineering for antigen presentation
- Clinical trial management (Phase I/II and adaptive designs)
Key Technologies
- Autologous cell-based vaccines
- Tumor-presenting cells (TPCs)
- MHC class II induction on tumor cells
- Cytokine-driven ex vivo cell culture